Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Praxis Precision Medicines Inc (NQ: PRAX )

1.050 +0.010 (+0.96%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 921,118
Open 1.060
Bid (Size) 1.030 (20)
Ask (Size) 1.060 (15)
Prev. Close 1.040
Today's Range 1.025 - 1.060
52wk Range 0.9810 - 13.33
Shares Outstanding 44,712,538
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank
The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest sectors that had deposits and financial relationships with the... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 6, 2023
 
Via Benzinga

Performance

YTD
-59.14%
-59.14%
1 Month
-68.84%
-68.84%
3 Month
-50.24%
-50.24%
6 Month
-60.08%
-60.08%
1 Year
-90.40%
-90.40%

More News

Read More
Praxis Precision Outlines Upcoming Plans For Pediatric Epilepsy Programs
Via Benzinga
Praxis Precision Medicines to Present at Upcoming Investor Conferences
From Praxis Precision Medicines, Inc.
Via Globe NewsWire
Dow Jumps Over 300 Points; S&P 500 Rises 1.5%
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Nasdaq Up 150 Points; Crude Oil Rises 1%
Via Benzinga
Why Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Dow Surges Over 100 Points; US Services PMI Rises In February
Via Benzinga
Despite Trial Failure Praxis Still Seeks Advancing Essential Tremor Program Into Phase 3 Study
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Praxis Precision Medicines Announces Topline Results from the Essential1 Study of Ulixacaltamide for the Treatment of Essential Tremor and Continued Advancement of Program to Phase 3
From Praxis Precision Medicines, Inc.
Via Globe NewsWire
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
From Praxis Precision Medicines, Inc.
Via Globe NewsWire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
US Stocks Edge Lower; Bank of America Profit Tops Views
Via Benzinga
Praxis Precision Medicines and UCB Announce Epilepsy Research Collaboration
From Praxis Precision Medicines, Inc.
Via Globe NewsWire
Praxis Precision Medicines to Present at the American Epilepsy Society 2022 Annual Meeting
From Praxis Precision Medicines, Inc.
Via Globe NewsWire
Praxis Precision Medicines to Advance PRAX-562 Phase 2 Study in Pediatric Patients with Developmental and Epileptic Encephalopathies
From Praxis Precision Medicines, Inc.
Via Globe NewsWire
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2022 Financial Results
From Praxis Precision Medicines, Inc.
Via Globe NewsWire
Praxis Precision Medicines to Present at Upcoming Investor Conferences
From Praxis Precision Medicines, Inc.
Via Globe NewsWire
Why Laser Photonics Shares Surged By Around 19%; Here Are 70 Biggest Movers From Friday
Via Benzinga
Ambit Inc. to Present Novel Projection Methodology for Rare Developmental and Epileptic Encephalopathies (DEEs) at the 2022 Child Neurology Society Annual Meeting
Via Newswire.com
Needham Previews Neurocrine's Upcoming Mid-Stage Data from Essential Tremor Study
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Via Benzinga
Tesla, Twitter And 76 Biggest Movers From Friday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.